Literature DB >> 11869325

Randomized controlled trial of intrasphincteric botulinum toxin A injection versus balloon dilatation in treatment of achalasia cardia.

U C Ghoshal1, S Chaudhuri, B B Pal, K Dhar, G Ray, P K Banerjee.   

Abstract

As the few randomized controlled trials available in the literature comparing botulinum toxin (BT) injection with established endoscopic treatment of achalasia cardia, i.e. pneumatic dilatation, showed conflicting results, we conducted a prospective randomized trial. Seventeen consecutive patients with achalasia cardia diagnosed during a period between December 1997 and February 2000 were randomized into two treatment groups [pneumatic dilatation by Rigiflex dilator (n=10), BT injection by sclerotherapy needle into four quadrants of lower esophageal sphincter (LES) (n=7) 80 units in five cases, 60 units in two cases] after dysphagia grading, endoscopy, barium esophagogram, and manometry, all of which were repeated 1 week after treatment. Patients were followed up clinically for 35.2+/-14 weeks. Chi-squares, Wilcoxon rank-sum test, Kaplan-Meier method and log-rank tests were used for statistical analysis. After 1 week, 6/7 (86%) BT-treated vs. 8/10 (80%) dilatation-treated patients improved (P=NS). There was no difference in LES pressure and maximum esophageal diameter in the barium esophagogram in the two groups before therapy. Both therapies resulted in significant reduction in LES pressure. The cumulative dysphagia-free state using the Kaplan-Meier method decreased progressively in BT-treated compared with dilatation-treated patients (P=0.027). Two patients with tortuous megaesophagus, one of whom had failed dilatation complicated by perforation previously, improved after BT. One other patient in whom pneumatic dilatation had previously failed improved in a similar manner. BT is as good as pneumatic dilatation in achieving an initial improvement in dysphagia of achalasia cardia. It is also effective in patients with tortuous megaesophagus and previous failed pneumatic dilatation. However, dysphagia often recurs during 1-year follow up.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11869325     DOI: 10.1046/j.1442-2050.2001.00189.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  22 in total

Review 1.  The use of botulinum toxin for the treatment of gastrointestinal motility disorders.

Authors:  Frank Friedenberg; Satya Gollamudi; Henry P Parkman
Journal:  Dig Dis Sci       Date:  2004-02       Impact factor: 3.199

Review 2.  Current status in the treatment options for esophageal achalasia.

Authors:  Seng-Kee Chuah; Chien-Hua Chiu; Wei-Chen Tai; Jyong-Hong Lee; Hung-I Lu; Chi-Sin Changchien; Ping-Huei Tseng; Keng-Liang Wu
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

Review 3.  Updated Systematic Review of Achalasia, with a Focus on POEM Therapy.

Authors:  Mitchell S Cappell; Stavros Nicholas Stavropoulos; David Friedel
Journal:  Dig Dis Sci       Date:  2019-08-27       Impact factor: 3.199

Review 4.  Therapeutic options in oesophageal dysphagia.

Authors:  Jan Tack; Giovanni Zaninotto
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-03-31       Impact factor: 46.802

5.  The use of the internet in data assimilation in rare diseases.

Authors:  Raymond Bedgood; Rafal Sadurski; Robert R Schade
Journal:  Dig Dis Sci       Date:  2007-01-11       Impact factor: 3.199

Review 6.  An update on the use of botulinum toxin therapy in Parkinson's disease.

Authors:  Reversa Mills; Laxman Bahroo; Fernando Pagan
Journal:  Curr Neurol Neurosci Rep       Date:  2015-01       Impact factor: 5.081

7.  Gastrointestinal Uses of Botulinum Toxin.

Authors:  Maria Cariati; Maria Michela Chiarello; Marco Cannistra'; Maria Antonietta Lerose; Giuseppe Brisinda
Journal:  Handb Exp Pharmacol       Date:  2021

8.  Endoscopic approach to achalasia.

Authors:  Michaela Müller; Alexander J Eckardt; Till Wehrmann
Journal:  World J Gastrointest Endosc       Date:  2013-08-16

9.  [Chronic motility disorders of the upper gastrointestinal tract in the elderly. Pharmaceutical, endoscopic and operative therapy].

Authors:  J-U Sonne; J F Erckenbrecht
Journal:  Internist (Berl)       Date:  2014-07       Impact factor: 0.743

10.  Predictors of a better outcome of pneumatic dilatation in patients with primary achalasia.

Authors:  Yuriko Tanaka; Katsuhiko Iwakiri; Noriyuki Kawami; Hirohito Sano; Mariko Umezawa; Makoto Kotoyori; Yoshio Hoshihara; Tsutomu Nomura; Masao Miyashita; Choitsu Sakamoto
Journal:  J Gastroenterol       Date:  2010-02       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.